Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1.

× No keyword cloud information.

22 in total

1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal: Ann Rheum Dis Date: 2006-11 Impact factor: 19.103

Review 2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal: Ann Rheum Dis Date: 2007-11 Impact factor: 19.103

3. Idiopathic inflammatory myopathy: treatment options.

Authors: Stephen J DiMartino
Journal: Curr Rheumatol Rep Date: 2008-08 Impact factor: 4.592

4. The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept.

Authors: Shengchun Zhao; Hongwei Chen; Guolin Wu; Chen Zhao
Journal: J Clin Lab Anal Date: 2017-01-23 Impact factor: 2.352

5. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Authors: Adam Schiffenbauer; Megha Garg; Christine Castro; Angelina Pokrovnichka; Galen Joe; Joseph Shrader; Imelda Victoria Cabalar; Sara Faghihi-Kashani; Michael O Harris-Love; Paul H Plotz; Frederick W Miller; Mark Gourley
Journal: Semin Arthritis Rheum Date: 2017-10-16 Impact factor: 5.532

6. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors.

Authors: G Chevrel; C Granet; P Miossec
Journal: Ann Rheum Dis Date: 2005-02-24 Impact factor: 19.103

Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1.

1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Review 2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

3. Idiopathic inflammatory myopathy: treatment options.

4. The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept.

5. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

6. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors.

7. A randomized, pilot trial of etanercept in dermatomyositis.

Review 8. Paediatric idiopathic inflammatory muscle disease: recognition and management.

Review 9. Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

10. Induction of muscle weakness by local inflammation: an experimental animal model.